Royal Bank of Canada
GLUE icon

Royal Bank of Canada’s Monte Rosa Therapeutics GLUE Stock Holding History

Royal Bank of Canada’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36K Sell
2,168
-650
-23% -$12.4K ﹤0.01% 5646
2025
Q4 		$44K Sell
2,818
-432,949
-99% -$5.83M ﹤0.01% 5618
2025
Q3 		$3.23M Sell
435,767
-34,031
-7% -$180K ﹤0.01% 3025
2025
Q2 		$2.12M Buy
469,798
+466,647
+14,809% +$2.08M ﹤0.01% 3250
2025
Q1 		$14K Sell
3,151
-2,452
-44% -$15K ﹤0.01% 6042
2024
Q4 		$39K Buy
5,603
+1,138
+25% +$8.54K ﹤0.01% 5807
2024
Q3 		$23K Buy
4,465
+278
+7% +$1.4K ﹤0.01% 6047
2024
Q2 		$16K Buy
4,187
+2,985
+248% +$15.2K ﹤0.01% 6156
2024
Q1 		$9K Sell
1,202
-9,916
-89% -$58.8K ﹤0.01% 6235
2023
Q4 		$63K Buy
11,118
+3,719
+50% +$14.6K ﹤0.01% 5884
2023
Q3 		$36K Buy
7,399
+3,711
+101% +$23.9K ﹤0.01% 5942
2023
Q2 		$25K Buy
3,688
+1,503
+69% +$9.72K ﹤0.01% 6089
2023
Q1 		$17K Sell
2,185
-3,030
-58% -$21.1K ﹤0.01% 6082
2022
Q4 		$39K Buy
5,215
+4,366
+514% +$36.4K ﹤0.01% 6025
2022
Q3 		$7K Buy
849
+187
+28% +$1.72K ﹤0.01% 6590
2022
Q2 		$7K Sell
662
-1,613
-71% -$16.2K ﹤0.01% 6519
2022
Q1 		$32K Sell
2,275
-1,080
-32% -$15K ﹤0.01% 6346
2021
Q4 		$68K Buy
3,355
+2,076
+162% +$43.5K ﹤0.01% 6194
2021
Q3 		$29K Buy
+1,279
New +$36.7K ﹤0.01% 6482

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Royal Bank of Canada's GLUE Position: Q1 2026 in Review

Royal Bank of Canada reduced its Monte Rosa Therapeutics (GLUE) stake by 23% in Q1 2026, selling an estimated $12.4K and leaving 2,168 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #5646.

Royal Bank of Canada first reported a position in GLUE in Q3 2021 and has held it in 19 quarters since. The position peaked at $3.23M in Q3 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Royal Bank of Canada held 2,168 shares of Monte Rosa Therapeutics worth $36K as of Q1 2026.
  • Royal Bank of Canada sold 650 Monte Rosa Therapeutics shares in Q1 2026, an estimated $12.4K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5646 holding.
  • Royal Bank of Canada first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • Royal Bank of Canada's Monte Rosa Therapeutics position peaked at $3.23M in Q3 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.